Advanced Accelerator Applications Overview
Pro stress-test →Advanced Accelerator Applications is a France-based pharmaceutical group specialized in nuclear medicine, operating across PET, SPECT, and therapy segments to diagnose and treat conditions in oncology, neurology, cardiology, and infectious/inflammatory diseases. Novartis acquired the company for $3.9 billion in January 2018.
Strategic Profile
Pro stress-test →The company's portfolio includes Lutathera (lutetium Lu 177 dotatate), a first-in-class radioligand therapy for neuroendocrine tumors, along with diagnostic products including NETSPOT and SOMAKIT. In May 2026, Siemens Healthineers agreed to acquire AAA's diagnostic arm for €200 million, leaving Novartis with only the radiotherapeutics operations.
Competitive Landscape
Pro stress-test →AAA is an established leader in molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT, mainly used in clinical oncology, cardiology and neurology. The company competes in the emerging radiopharmaceutical therapeutics space with limited direct competitors, though the May 2026 diagnostic divestiture narrows its competitive scope to radioligand therapy.
Industry Context
Advanced Accelerator Applications operates in Radiopharmaceuticals / Nuclear Medicine.
Key facts
Founded: 2002 · Headquarters: Saint-Genis-Pouilly, FR · Employees: N/A · Revenue: N/A · Market cap: N/A